Here's what to know about Medicare's new GLP-1 weight-loss drug program
For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 monthly copay.
Watch CBS News
For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 monthly copay.
As obesity rates among Americans drop and weight loss drugs lead to a slimmer society, airlines could save on fuel costs, according to a recent analysis.
FDA-approved semaglutide drug is the first GLP-1 pill for weight loss available in the U.S., according to drugmaker Novo Nordisk.
The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month in some cases, officials said.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.
As artificial intelligence continues to evolve, especially here in the Bay Area, one lab is working to use AI technology to find the next effective weight loss drug.
As artificial intelligence continues to evolve, especially here in the Bay Area, one lab is working to use AI technology to help people lose weight without the common unwanted side effects. Sooji Nam reports.
Do weight loss drug labels warn enough about potential side effects? A patient who needed emergency surgery is suing prescription drugmaker Novo Nordisk.
A group of weight loss and diabetes treatment drugs, known as GLP-1 agonists, work by curbing appetite centers in the brain. But animal studies suggest these drugs could also potentially reduce addiction to nicotine, alcohol, and opioids. Dr. Jon LaPook explains.
Semaglutide, the active ingredient in drugs like Wegovy and Ozempic, can help people lose weight — and a new study says it may also help people quit smoking.
Novo Nordisk and Lilly can't keep up with demand for their weight loss drugs such as Ozempic, Wegovy and Mounjaro. But they object to specialty pharmacies making their own cheaper versions to fill the gap — providing as much as 30% of those drugs sold in the U.S.
With weight loss drugs Ozempic and Wegovy in short supply, a startup is offering their own version that has yet to be approved by the FDA, raising concerns from a Stanford doctor. Nancy Chen reports. Website: http://kpix.com/ YouTube: http://www.youtube.com/CBSSanFrancisco Facebook: https://www.facebook.com/CBSSanFrancisco Instagram: https://www.instagram.com/kpixtv/ Twitter: https://twitter.com/KPIXtv
GLP-1 class medications reduce cardiovascular risk and treat diabetes. But they also allow people to lose an average of 10-20 percent of their body weight in the first year. What does that mean for the overweight or obese?
Ozempic and other GLP-1 RA drugs, including Wegovy, Mounjaro and Zepbound, are being scrutinized.
From the Ozempic "ripple effect" to health tech and more, experts share their predictions for 2024 wellness trends.
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
The warning about scams comes as sales have boomed for Ozempic, Wegovy and other drugs used for weight loss.
A personal injury law firm filed a suit against Novo Nordisk and Eli Lilly and Co., the manufacturers of Ozempic and Mounjaro.
